Justification and selection of a hepatoprotective agent for the complex therapy of patients with psoriasis
- Authors: Kokhan M.M.1, Filimonkova N.N.1, Kiseleva N.V.1, Gilyazova I.N.1
-
Affiliations:
- Ural Research Institute of Dermatovenereology and Immunopathology
- Issue: Vol 32, No 5 (2025)
- Pages: 94-100
- Section: Original articles
- URL: https://journals.rcsi.science/2073-4034/article/view/316498
- DOI: https://doi.org/10.18565/pharmateca.2025.5.94-100
- ID: 316498
Cite item
Abstract
Background: Psoriasis is a common chronic multifactorial, immune-mediated inflammatory skin disease, often associated with a high risk of developing comorbid cardiovascular diseases, metabolic syndrome, as well as liver pathology, including iatrogenic, ari-sing in the process of systemic therapy, which is reflected in a brief review of domestic and foreign publications.
Objective: Evaluation of the nature and severity of systemic inflammation indicators and the profile of changes in the blood serum lipid spectrum in patients with severe psoriasis, justification of the choice of a hepatoprotective agent with a pathogenetically justified complex effect.
Materials and methods: A clinical and laboratory examination of patients with severe psoriasis (PASI index over 20 points) with an assessment of hemogram indicators, biochemical hepatogram, including peripheral blood lipidogram, group and subgroup data analysis using the Statistica 10 program was conducted.
Results: In patients with severe clinical manifestations of psoriasis (in the absence of joint lesions), a pronounced proinflammatory reaction of the peripheral blood with an increase in the neutrophil/lymphocyte ratio in combination with a high serum CRP-ultra level was established. It was shown that the presence of immune-mediated inflammation in this cohort of patients with psoriasis was combined with high atherogenic lipidogram indices and reduced serum phospholipid levels, which are “predictors” of the formation of comorbid cardiovascular and liver pathology.
Conclusion: The results of the study confirm the need to include a hepatoprotector in the complex therapy of patients with psoriasis and justify the choice of a drug containing essential phospholipids and glycyrrhizic acid, which is determined by the pharmacological properties of this drug providing both a “replacement”, hepatoprotective, and anti-inflammatory effect in psoriasis and comorbid conditions.
Full Text
##article.viewOnOriginalSite##About the authors
Muza M. Kokhan
Ural Research Institute of Dermatovenereology and Immunopathology
Author for correspondence.
Email: mkokhan@yandex.ru
ORCID iD: 0000-0001-6353-6644
Dr. Sci. (Med.), Professor, Head of the Scientific Clinical Department of Dermatology
Russian Federation, YekaterinburgN. N. Filimonkova
Ural Research Institute of Dermatovenereology and Immunopathology
Email: nnfil2008@mail.ru
ORCID iD: 0000-0003-2872-3836
Dr. Sci. (Med.), Professor, Leading Researcher of the Scientific Clinical Department of Dermatology
Russian Federation, YekaterinburgN. V. Kiseleva
Ural Research Institute of Dermatovenereology and Immunopathology
Email: enkisa@rambler.ru
ORCID iD: 0000-0002-2609-7977
Researcher, Experimental Laboratory Department
Russian Federation, YekaterinburgI. N. Gilyazova
Ural Research Institute of Dermatovenereology and Immunopathology
Email: inna.gilyazova@list.ru
ORCID iD: 0009-0003-7781-6147
Junior Researcher, Scientific Clinical Department of Dermatology
Russian Federation, YekaterinburgReferences
- Lowes M.A., Bowcock A.M., Krueger J.G. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866–73. https://doi.org/10.1038/nature05663
- Furue M., Tsuji G., Chiba T., Kadono T. Cardiovascular and metabolic diseases comorbid with psoriasis: Beyond the skin. Intern Med. 2017;56 (13):1613–9. https://doi.org/10.2169/internalmedicine.56.8209
- Ойноткинова О.Ш., Ройтберг Г.Е., Шархун О.О. и др. Сердечно-сосудистый риск у коморбидных пациентов с псориазом и метаболическим синдромом. Эффективная фармакотерапия. 2024;20(43):70–6. [Oinotkinova O.Sh., Roitberg G.E., Sharkhun O.O. et al. Serdechno-sosudistyi risk u komorbidnykh patsientov s psoriazom i metabolicheskim sindromom. Effektivnaya Farmakoterapiya. 2024;20 (43):70–76 (In Russ.)]. https://doi.org/10.33978/2307-3586-2024-20-43-70-76
- Al-Harbi N.O., Nadeem А., Al-Harbi М.М., et al. Psoriatic inflammation causes hepatic inflammation with concomitant dysregulation in hepatic metabolism via IL-17A/IL-17 receptor signaling in a murine model. Immunobiology. 2017;222(2):128–36. https://doi.org/10.1016/j.intimp.2017.02.018
- Tula Е., Ergun Т., Seckin D., et al. Psoriasis and the liver: problems, causes and course. Australasian J Dermatol. 2017;58(3):194–9. https://doi.org/10.1111/ajd.12460
- Fiore M., Leone S., Maraolo A.E., et al. Liver Illness and Psoriatic Patients. BioMed Res Intern. 2018;2018;3140983. https://doi.org/10.1155/2018/3140983
- Conway R., Carey J. Risk of liver disease in methotrexate treated patients. World J Hepatol. 2017;9(26):1092. https://doi.org/10.4254/wjh.v9.i26.1092
- Асоскова А.В., Сычев Д.А., Кубанов А.А. Вопросы безопасности применения метотрексата в терапии псориаза. Вестник РАМН. 2021;76(3):254–67. [Asoskova A.V., Sychev D.A., Kubanov A.A. Voprosy bezopasnosti primeneniya metotreksata v terapii psoriaza. Vestn RAMN. 2021;76(3):254–67. (In Russ.)]. https://doi.org/https://doi.org/10.15690/vramn1527
- Shetty A., Cho W., Alazawi W., et al. Methotrexate hepatotoxicity and the impact of nonalcoholic fatty liver disease. Am J Med Sci. 2017;354(2):172–80. https://doi.org/10.1016/j.amjms.2017.03.014
- Kim B.R., Yang S., Doh E.J., et al. Risk factors affecting adverse effects of cyclosporine A in a real-world psoriasis treatment. Ann Dermatol. 2018;30(2):143–9. https://doi.org/10.3389/fonc.2022.889433
- Zhou W., Chen X., Zhao G., et al. Psoralen induced liver injury by attenuating liver regenerative capability. Front Pharmacol. 2018;9:1179. https://doi.org/10.3389/fphar.2018.01179
- Ogdie A., et al. Risk of Incident Liver Disease in Patients with Psoriasis, Psoriatic Arthritis, and Rheumatoid Arthritis: A Population-Based Study. J Invest Dermatol. 2018;138:760–7. https://doi.org/10.1016/j.jid.2017.10.024
- Круглова Л.С., Руднева Н.С., Егоян Г.Г. Вопросы применения гепатопротекторов при псориазе: показания и эффективность. Медицинский алфавит. 2022;(8):61–6. [Kruglova L.S., Rudneva N.S., Egoyan G.G. Voprosy primeneniya gepatoprotektorov pri psoriaze: pokazaniya i effektivnost’. Meditsinskii Alfavit. 2022;(8):61–6. (In Russ.)]. https://doi.org/10.33667/2078-5631-2022-8-61-66
- Корсунская И.М., Пирузян А.Л., Сакания Л.Р. и др. Роль глицирризиновой кислоты в патогенезе псориатической болезни Эффективная фармакотерапия. 2016;13:22–8. [Korsunskaya I.M., Piruzyan A.L., Sakaniya L.R., et al. Rol’ glitsirrizinovoi kisloty v patogeneze psoriaticheskoi bolezni. Effekt Farmakoter. 2016; 13:22–8. (In Russ.)].
- Huong N.T.K., Long B., Doanh L.H., et al. Associations of different inflammatory factors with atherosclerosis among patients with psoriasis vulgaris. Front Med. 2024;11:1396680. https://doi.org/10.3389/fmed.2024.1396680
- Roy P., Orecchioni M., Ley K. How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. Nat Rev Immunol. 2022;22:251–65. https://doi.org/10.1038/s41577-021-00584
- Ataseven A., Bilgin A. U., Kurtipek G.S., et al. The Importance of Neutrophil Lymphocyte Ratio in Patients with Psoriasis. Clin Med Res. 2014;3(2):40–3. doi: 10.11648/j.cmr.20140302.17
- Zhou G., Ren X., Tang Z., et al. Exploring the association and causal effect between white blood cells and psoriasis using large-scale population data. Front Immunol. 2023;14:1043380. https://doi.org/10.3389/fimmu.2023.1043380
- Nowowiejska J., Baran A., Flisiak I. Aberrations in Lipid Expression and мetabolism in Psoriasis. Int J Mol Sci. 2021;22:6561. https://doi.org/10.3390/ijms22126561
- Круглова Л.С., Львов А.Н., Аравийская Е.Р. и др. Вопросы применения гепатопротекторов в дерматологии (резолюция совета экспертов). Кремлевская медицина. Клинический вестник. 2024;4:6–14. [Kruglova L.S., L’vov A.N., Araviiskaya E.R., et al. Voprosy primeneniya gepatoprotektorov v dermatologii (rezolyutsiya soveta ekspertov). Kremlevskaya meditsina. Klinicheskii Vestnik. 2024;4:6–14. (In Russ.)]. doi: 10.48612/cgma/ e4p2-vt28-akv1
- Инструкция по медицинскому применению лекарственного препарата Фосфоглив®. [Instructions for medical use of the medicinal product Phosphogliv®. (In Russ.)]. URL: https://www.rlsnet.ru/drugs/fosfogliv-9263?ysclid=mbnsfjy2s2662520415; доступ 10.06.2025.
Supplementary files
